Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Makes Only Limited Use Of Remote Clinical Trial Monitoring

Executive Summary

While regulators worldwide are opening up to the possibility of remote verification of source data from clinical trial sites because of COVID-19 restrictions, this approach is finding less favor in the EU, mainly because of strict data protection rules.

You may also be interested in...



EU Takes Focused Approach In Bid To Deliver Decentralized Clinical Trials Guide By Year End

EU regulators are eager to roll out harmonized requirements for decentralized clinical trials by the end of 2022 and so have decided to tackle some of the notably trickier issues in greater detail later on.

US FDA Raises Problems With EU Data Protection Reg, But Are They Among Those Misunderstanding It?

An FDA blog post says some inspections have been hindered and application assessments soon could be delayed by the EU General Data Protection Regulation (GDPR), but experts argue the law includes directions to allow data sharing and remain compliant.

Companies Urged Not To View EU Privacy Law As A Barrier To Conducting Decentralized Trials

A senior regulator from the European Medicines Agency says that while the EU General Data Protection Regulation can be intellectually challenging, the law is needed, and it should not deter companies from conducting decentralized clinical trials because of concerns they might have over the use of digital tools to capture and process patient and trial data.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel